- Trials with a EudraCT protocol (8,106)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8,106 result(s) found for: Cancer Diseases.
Displaying page 12 of 406.
| EudraCT Number: 2009-015628-27 | Sponsor Protocol Number: CAUY922A2109 | Start Date*: 2010-08-25 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha... | ||||||||||||||||||
| Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-005073-37 | Sponsor Protocol Number: I-1409 | Start Date*: 2015-02-02 | ||||||||||||||||||||||||||
| Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital | ||||||||||||||||||||||||||||
| Full Title: 68Ga-PSMA PET/CT for detection of recurrent prostate cancer: Comparison with 18F-fluoride PET/CT, MRI and DW-MRI | ||||||||||||||||||||||||||||
| Medical condition: Patients diagnosed with biochemical (PSA) relapse following curative intended treatment (defined as radical prostatectomy or radiotherapy, either by external beam radiotherapy or low- or high-dose ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2016-005147-17 | Sponsor Protocol Number: AIO-PAK-0216 | Start Date*: 2018-01-30 | ||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||||||||||||
| Full Title: Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy | ||||||||||||||||||||||||||||
| Medical condition: locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2015-002296-18 | Sponsor Protocol Number: CaTo-ROC | Start Date*: 2015-07-30 | |||||||||||
| Sponsor Name:Vejle Hospital, Department of Oncology | |||||||||||||
| Full Title: Cabazitaxel in patients with Recurrent Ovarian Cancer after failure of standard therapy- A phase II trial | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000304-96 | Sponsor Protocol Number: NL47648.029.14 | Start Date*: 2015-01-15 | |||||||||||
| Sponsor Name:VU University Medical Center (VUmc) | |||||||||||||
| Full Title: Sentinel lymph node identification in colon cancer using a radioactive and fluorescent tracer | |||||||||||||
| Medical condition: Colon Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001263-12 | Sponsor Protocol Number: FoRT01/2014 | Start Date*: 2014-08-07 | |||||||||||
| Sponsor Name:Fondazione Ricerca Traslazionale (FoRT) | |||||||||||||
| Full Title: Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) | |||||||||||||
| Medical condition: Pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002348-26 | Sponsor Protocol Number: MA1214 | Start Date*: 2012-08-20 | |||||||||||
| Sponsor Name:Danish Breast Cancer Group (BDCG) | |||||||||||||
| Full Title: Phase II study of irinotecan weekly in patients with locally advanced or metastatic HER2-negative breast cancer and increased cancer cell copy number of the topoisomerase 1 gene (TOP1)” | |||||||||||||
| Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001382-40 | Sponsor Protocol Number: Metform01 | Start Date*: 2011-09-09 | |||||||||||
| Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study | |||||||||||||
| Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-006108-11 | Sponsor Protocol Number: PM1183-B-003-11 | Start Date*: 2012-04-03 | |||||||||||
| Sponsor Name:Pharma Mar, S.A. | |||||||||||||
| Full Title: A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. | |||||||||||||
| Medical condition: BRCA1 / BRCA2 associated or unselected Metastatic Breast Cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004858-18 | Sponsor Protocol Number: Toco-Ovar | Start Date*: 2014-12-19 | |||||||||||
| Sponsor Name:Vejle Hospital | |||||||||||||
| Full Title: Tocotrienol as a nutritional supplement in patients with advanced ovarian cancer | |||||||||||||
| Medical condition: Chemotherapy resistant ovarian cancer with progressive disease. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003898-98 | Sponsor Protocol Number: PDD_vs_WL-TURB_in_pazienti_con_NMIB | Start Date*: 2013-11-28 | |||||||||||
| Sponsor Name:Ospedale San Raffaele | |||||||||||||
| Full Title: COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) | |||||||||||||
| Medical condition: high grade non muscle invasive bladder cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003505-10 | Sponsor Protocol Number: ERIGE | Start Date*: 2013-04-24 | |||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA | |||||||||||||
| Full Title: Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE. | |||||||||||||
| Medical condition: Locally recurrent or metastatic triple negative breast cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004020-21 | Sponsor Protocol Number: PR-Trab-PT | Start Date*: 2015-04-01 | |||||||||||
| Sponsor Name:Fundación para la investigación biomédica del Hospital Clínico San Carlos | |||||||||||||
| Full Title: Reintroduction of platinum-based therapy after treatment with trabectedin in patients with relapsed ovarian cancer resistant to platinum | |||||||||||||
| Medical condition: Ovarian cancer resistant to the treatment with platinum | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002347-23 | Sponsor Protocol Number: MA1213 | Start Date*: 2012-08-20 | |||||||||||
| Sponsor Name:Danish Breast Cancer Group (DBCG) | |||||||||||||
| Full Title: Phase II study of irinotecan weekly in combination with trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer and increased cancer cell copy number of TOP1” | |||||||||||||
| Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-004405-25 | Sponsor Protocol Number: HIPEC_Stomach | Start Date*: 2012-03-01 | ||||||||||||||||
| Sponsor Name:University Hospital Tübingen | ||||||||||||||||||
| Full Title: Study for prevention of peritoneal carcinomatosis in patients with stomach cancer | ||||||||||||||||||
| Medical condition: Reducing the risk of peritoneal carcinomatosis in patients with stomach cancer with following treatment: gastrectomy incl. HIPEC vs. gastrectomy excl. HIPEC | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-003559-39 | Sponsor Protocol Number: ICO-A-2018-10 | Start Date*: 2018-12-11 | |||||||||||
| Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
| Full Title: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains a... | |||||||||||||
| Medical condition: men and /or women older than 18 years with breast cancer for which a surgical operation was realized. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003883-36 | Sponsor Protocol Number: CFTSp104 | Start Date*: 2017-02-01 | |||||||||||
| Sponsor Name:The Christie NHS Foundation Trust | |||||||||||||
| Full Title: Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer | |||||||||||||
| Medical condition: platinum sensitive BRCAm high grade serous ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003043-29 | Sponsor Protocol Number: MITO-16/MaNGO-OV2 | Start Date*: 2012-09-24 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
| Full Title: A multicenter study in patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors | |||||||||||||
| Medical condition: advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-024067-41 | Sponsor Protocol Number: COLTONE | Start Date*: 2011-04-28 | |||||||||||
| Sponsor Name:F.A.R.O. FONDAZIONE PER LE ATTIVITA' DI RICERCA IN ONCOLOGIA | |||||||||||||
| Full Title: Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis... | |||||||||||||
| Medical condition: Elderly patients with diagnosis of early breast Cancer candidate to adjuvant chemotherapy. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001566-21 | Sponsor Protocol Number: 4767 | Start Date*: 2018-01-29 | |||||||||||
| Sponsor Name:Ismail Gögenur [...] | |||||||||||||
| Full Title: Effect of Low-dose Interferon-alfa2a on post-operative immune suppression - a randomized trial | |||||||||||||
| Medical condition: Colon cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.